Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Slides:



Advertisements
Similar presentations
Traitement de l’Hépatite C Sans Interféron Patrick Marcellin.
Advertisements

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.
Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.
Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.
The Hepatitis B&C Past and Present Martin J Spitz MD FACP AGAF Clinical Professor of Medicine UCSF.
LIVER CENTRE Toronto Western Site David Wong, MD University of Toronto TWH Francis Family Liver Clinic TGH Immunodeficiency Clinic SM Positive Care Clinic.
Management of Chronic Hepatitis C in 2013
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.
Liver Institute of Virginia Education, Research and Treatment for Patients with Liver Disease IVer Bon Secours Health System WHY CHOOSE TELAPREVIR Mitchell.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 2 Robert G. Gish MD Staff Physician, Stanford University.
Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.
Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.
VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.
Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.
OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.
NS5A and polymerase inhibitors Mark Sulkowski, MD Professor of Medicine Johns Hopkins University Baltimore Maryland
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
Hepatitis C Nonresponders
Pierluigi Toniutto Medical Liver Transplant Section University of Udine OPTIMIZING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C LOOKING AT THE FUTURE OF IFN.
AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit.
Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.
David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.
 Design  Objective –Difference in SVR ≥ 40% between the 2 groups, 99% power SOF + RBV Placebo Randomisation 3 : 1* Double blind HCV infection Genotype.
SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
Treatment of Chronic HCV Genotype 3
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study
 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Milan, Italy ELPA Symposium: COMPASSIONATE USE IN HEPATITIS C What patients populations.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis
Design No randomisation Open-label W12 W years HCV genotype 1
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years
Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3
Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014
Future Trials of Hepatitis C Therapy in the HIV Co-infected
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1
Resistance to Direct Acting Antiviral Therapy
Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE
Therapeutic Background & Study Rationale
Out With the Old and In With the New, Again?
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Phase 3 Treatment-Naïve and Treatment-Experienced
Obiettivi e strategie di un
LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II
Phase 2 Treatment Naïve and Treatment Experienced
PI-Based HCV-1 Therapy: Reasons to Hold Off
ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.
MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB
Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study
No HBV or HIV co-infection
CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1
Presentation transcript:

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California San Diego Don’t Blink: The Rapid Evolution of IFN-Free Therapy for HCV From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA.

Slide 2 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. Why do we need IFN-free regimens? Efficacy Poorly interferon responsive – African Americans – Prior IFN failure Null responder cirrhotics Acceptance and tolerability Poor patient acceptance Providers reluctance – Resource intensive Monitoring: toxicity Support services Interferon ineligible populations Decompensated ESLD Severe psychiatric disease Medical co-morbidities 100 HCV RNA+ Patients 40 Eligible Patients 5 Cured 30% refusal 75% dropout or nonresponse 60% Ineligible 28 Treated Falck-Ytter, Y. Annals, 2002.

Slide 3 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. Limitation of first generation PIs Complicated dosing regimens and treatment algorithms – Food restrictions High potential for drug-drug interactions Increased side effects (over Peg/RBV) Limited efficacy in those with the greatest medical need

Slide 4 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. Retreatment Success Depends on Fibrosis Stage and Previous Response Zeuzem S. NEJM TVR-based therapy; HCV mono-infected

Slide 5 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. BOC and TVR Increase Adverse Events Jacobson I. NEJM 2011; Poordad F. NEJM Adverse Event, %TVR Arms (n = 727) PegIFN/RBV Arm (n = 361) Pruritus Nausea Rash Anemia Diarrhea Discontinuation due to AE91 Adverse Event, %BOC Arms (n = 78) PegIFN/RBV Arm (n = 363) Anemia4929 Dysgeusia Discontinuation due to AE1416 Telaprevir (TVR) Boceprevir (BOC)

Slide 6 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IFN-Free Regimens for HCV gt1 DrugsClassesPopulationDurationN SVR (1a/1b) Daclatasvir/ Asunaprevir NS5A/PI Nulls IFN intolerant 24 wks % (22/100) 77% DCV/ASU/ BMS NS5A/PI/N NI Naïve Non-cirrhotic 12 wks 24wks 16 94% 94% $ SOF/RBVNI Naïve Nulls 12 wks % 10% SOF/RBV GT 2/3 NI Naïve/intolerant Non-responders 12 wks 12/16 wks /95 67% (97/56) 50/73% SOF/DCV±RBV SOF/LDV/RBV NI/NS5A Naïve Naïve/Null 24wks 12wks 44 25/ % 100/100% SOF/SMV±RBVNI/PI Null (F0-F2) 12wks % * 93% * FAL/ BI /RBV PI/NNI Naïve Cirrhosis 28 wks7868% (43/83) Mericitabine/ Danoprevir + RBV NI/PI Naïve (F0-F2) 24 wks6441% (26/71) ABT-450r/267/ 333±RBV PI/NS5A/N NI Naïve Nulls % 93% Lok A. NEJM Suzuki F. #14 EASL Everson G. AASLD Gane EJ AASLD Gilead press release Feb Sulkowski M. AASLD Gane EJ. CROI Lawitz E CROI Zeuzem S. #101 EASL Poordad F. EASL King M. CROI $ SVR 4 * SVR 8

Slide 7 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. Lessons learned with IFN-free therapies HCV cure is achievable without IFN – With much shorter durations Subtype matters with less potent regimens Ribavirin matters with less potent regimens Cirrhotics and null responders can be effectively treated Tolerability and side effects are improved

Slide 8 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. Unknowns with IFN-free therapies Efficacy in HCV/HIV subjects – No reason to suspect efficacy will suffer – Drug-drug interaction limiting factor How restrictive will payers be? – SOF + DCV or SOF + SMV “off label” early 2014 Impact of selected HCV resistance? Decompensated cirrhosis data needed